Studies of the mode of action of antitumour triazenes and triazines - III. Metabolism studies on hexamethylmelamine

C. Brindley, A. Gescher, S. P. Langdon, M. Broggini, T. Colombo, M. D'Incalci

Research output: Contribution to journalArticle

Abstract

There is good evidence that the antitumor agent hexamethylmelamine (HMM) undergoes oxidative activation which might occur in the liver and/or extrahepatically. The hepatic microsomal N-methylmelamine metabolizing enzymes were investigated in mice and exhibited different affinities for different melamine derivatives. The apparent K(m) values are 0.09 mM for HMM, 0.23 mM for pentamethylmelamine, 0.91 mM for 2,2,4,6-tetramethylmelamine and 1.7 mM for trimethylmelamine. HMM inhibited its own mechanism in vitro at substrate concentrations >0.5 mM. Its hepatic microsomal N-methylation rate was reduced when the mice were pretreated with hepatic glutathione depleting agent methyliodide. Injection of hexaethylmelamine, a derivative of HMM without antineoplastic properties against the M5076 sarcoma in mice, lead to plasma concentrations of drug and metabolite pentaethylmelamine which were only a fraction of the drug and metabolite levels achieved after a similar dose of HMM.

Original languageEnglish
Pages (from-to)625-631
Number of pages7
JournalBiochemical Pharmacology
Volume31
Issue number5
DOIs
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Studies of the mode of action of antitumour triazenes and triazines - III. Metabolism studies on hexamethylmelamine'. Together they form a unique fingerprint.

  • Cite this